DISPEL: A Python Framework for Developing Measures From Digital Health Technologies

IEEE Open J Eng Med Biol. 2024 May 17:5:494-497. doi: 10.1109/OJEMB.2024.3402531. eCollection 2024.

Abstract

Goal: This paper introduces DISPEL, a Python framework to facilitate development of sensor-derived measures (SDMs) from data collected with digital health technologies in the context of therapeutic development for neurodegenerative diseases. Methods: Modularity, integrability and flexibility were achieved adopting an object-oriented architecture for data modelling and SDM extraction, which also allowed standardizing SDM generation, naming, storage, and documentation. Additionally, a functionality was designed to implement systematic flagging of missing data and unexpected user behaviors, both frequent in unsupervised monitoring. Results: DISPEL is available under MIT license. It already supports formats from different data providers and allows traceable end-to-end processing from raw data collected with wearables and smartphones to structured SDM datasets. Novel and literature-based signal processing approaches currently allow to extract SDMs from 16 structured tests (including six questionnaires), assessing overall disability and quality of life, and measuring performance outcomes of cognition, manual dexterity, and mobility. Conclusion: DISPEL supports SDM development for clinical trials by providing a production-grade Python framework and a large set of already implemented SDMs. While the framework has already been refined based on clinical trials' data, ad-hoc validation of the provided algorithms in their specific context of use is recommended to the users.

Keywords: Signal processing; balance; cognition; digital biomarkers; digital health technology; drawing; gait; inertial sensor; python; smartphone; wearable sensing.

Grants and funding

The work of S. Del Din was supported by the the Innovative Medicines Initiative 2 Joint Undertaking (JU) through Mobilise-D Project under Grant 820820, in part by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust and in part by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. The work of S. Del Din and C. Hinchliffe was supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) through Project IDEA-FAST under Grant 853981. This work was supported by Biogen Digital Health. The JU was supported by the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).